Healthcare / Drug Manufacturers - Specialty & GenericBSE
$776.75
-13.85 (-1.75%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-1.3B · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
46/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$39.4B
P/E
196.1x
↑EV/EBITDA
61.6x
↑ROE
1.6%
↑Gross Margin
35.2%
↓Debt/Equity
0.28
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+6.8%
FCF CAGR
—
FCF margin
-34.8%
FCF / Net income
-13.74x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $8.11B · net income $205.5M · FCF $-2.82B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $8.11B | $8.11B | $9.22B | $8.19B | $6.66B |
| Net Income | $205.5M | $205.5M | $996.6M | $921.7M | $463.2M |
| EBITDA | $697.3M | $697.3M | $1.45B | $1.42B | $1.42B |
| EPS | — | — | 19.65 | 19.06 | 11.35 |
| Gross Margin | 35.2% | 35.2% | 41.0% | 39.2% | 40.4% |
| Operating Margin | 19.5% | 19.5% | 27.9% | 9.6% | 4.5% |
| Net Margin | 2.5% | 2.5% | 10.8% | 11.3% | 7.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.28 | 0.28 | 0.14 | 0.12 | 0.48 |
| Cash Flow | |||||
| Free Cash Flow | $-2.82B | $-2.82B | $-1.31B | $611.8M | $-665.8M |
| Returns | |||||
| ROE | 1.6% | 1.6% | 7.9% | 7.9% | 6.7% |
| Valuation | |||||
| P/E | 196.15 | 196.15 | 38.55 | 58.31 | 34.37 |
| EV/EBITDA | 61.60 | 61.60 | 27.62 | 38.90 | 13.36 |
| P/B | 3.06 | 3.06 | 3.03 | 4.60 | 2.31 |
| Growth & Yield | |||||
| Revenue Growth | -12.0% | -12.0% | 12.6% | 23.0% | — |
| EPS Growth | — | — | 3.1% | 67.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+3.0%
Start / end P/E
n/dx → n/dx
EPS bridge
19.65 → n/d
Residual
+3.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.